These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 37326376)

  • 21. Rare codons capacitate Kras-driven de novo tumorigenesis.
    Pershing NL; Lampson BL; Belsky JA; Kaltenbrun E; MacAlpine DM; Counter CM
    J Clin Invest; 2015 Jan; 125(1):222-33. PubMed ID: 25437878
    [TBL] [Abstract][Full Text] [Related]  

  • 22. YTHDF1 Promotes Cyclin B1 Translation through m
    Lou X; Ning J; Liu W; Li K; Qian B; Xu D; Wu Y; Zhang D; Cui W
    Cells; 2021 Jul; 10(7):. PubMed ID: 34359836
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oncogenic KRAS is dependent upon an EFR3A-PI4KA signaling axis for potent tumorigenic activity.
    Adhikari H; Kattan WE; Kumar S; Zhou P; Hancock JF; Counter CM
    Nat Commun; 2021 Sep; 12(1):5248. PubMed ID: 34504076
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oncogenic context shapes the fitness landscape of tumor suppression.
    Blair LM; Juan JM; Sebastian L; Tran VB; Nie W; Wall GD; Gerceker M; Lai IK; Apilado EA; Grenot G; Amar D; Foggetti G; Do Carmo M; Ugur Z; Deng D; Chenchik A; Paz Zafra M; Dow LE; Politi K; MacQuitty JJ; Petrov DA; Winslow MM; Rosen MJ; Winters IP
    Nat Commun; 2023 Oct; 14(1):6422. PubMed ID: 37828026
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Thrombospondin-1 mediates oncogenic Ras-induced senescence in premalignant lung tumors.
    Baek KH; Bhang D; Zaslavsky A; Wang LC; Vachani A; Kim CF; Albelda SM; Evan GI; Ryeom S
    J Clin Invest; 2013 Oct; 123(10):4375-89. PubMed ID: 24018559
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Critical requirement of SOS1 for tumor development and microenvironment modulation in KRAS
    Baltanás FC; García-Navas R; Rodríguez-Ramos P; Calzada N; Cuesta C; Borrajo J; Fuentes-Mateos R; Olarte-San Juan A; Vidaña N; Castellano E; Santos E
    Nat Commun; 2023 Sep; 14(1):5856. PubMed ID: 37730692
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Functional Taxonomy of Tumor Suppression in Oncogenic KRAS-Driven Lung Cancer.
    Cai H; Chew SK; Li C; Tsai MK; Andrejka L; Murray CW; Hughes NW; Shuldiner EG; Ashkin EL; Tang R; Hung KL; Chen LC; Lee SYC; Yousefi M; Lin WY; Kunder CA; Cong L; McFarland CD; Petrov DA; Swanton C; Winslow MM
    Cancer Discov; 2021 Jul; 11(7):1754-1773. PubMed ID: 33608386
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Human lung epithelial cells progressed to malignancy through specific oncogenic manipulations.
    Sato M; Larsen JE; Lee W; Sun H; Shames DS; Dalvi MP; Ramirez RD; Tang H; DiMaio JM; Gao B; Xie Y; Wistuba II; Gazdar AF; Shay JW; Minna JD
    Mol Cancer Res; 2013 Jun; 11(6):638-50. PubMed ID: 23449933
    [TBL] [Abstract][Full Text] [Related]  

  • 29. IL6 Blockade Reprograms the Lung Tumor Microenvironment to Limit the Development and Progression of K-ras-Mutant Lung Cancer.
    Caetano MS; Zhang H; Cumpian AM; Gong L; Unver N; Ostrin EJ; Daliri S; Chang SH; Ochoa CE; Hanash S; Behrens C; Wistuba II; Sternberg C; Kadara H; Ferreira CG; Watowich SS; Moghaddam SJ
    Cancer Res; 2016 Jun; 76(11):3189-99. PubMed ID: 27197187
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel activating KRAS mutation candidates in lung adenocarcinoma.
    Abe J; Tanuma N; Nomura M; Ito S; Kasugai I; Sato I; Tamai K; Mochizuki M; Yamaguchi K; Shima H; Okada Y; Yasuda J
    Biochem Biophys Res Commun; 2020 Feb; 522(3):690-696. PubMed ID: 31787238
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rapid acceleration of KRAS-mutant pancreatic carcinogenesis via remodeling of tumor immune microenvironment by PPARδ.
    Liu Y; Deguchi Y; Wei D; Liu F; Moussalli MJ; Deguchi E; Li D; Wang H; Valentin LA; Colby JK; Wang J; Zheng X; Ying H; Gagea M; Ji B; Shi J; Yao JC; Zuo X; Shureiqi I
    Nat Commun; 2022 May; 13(1):2665. PubMed ID: 35562376
    [TBL] [Abstract][Full Text] [Related]  

  • 32. miR-301a promotes lung tumorigenesis by suppressing Runx3.
    Li X; Zhong M; Wang J; Wang L; Lin Z; Cao Z; Huang Z; Zhang F; Li Y; Liu M; Ma X
    Mol Cancer; 2019 May; 18(1):99. PubMed ID: 31122259
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impaired AKT signaling and lung tumorigenesis by PIERCE1 ablation in KRAS-mutant non-small cell lung cancer.
    Roh JI; Lee J; Sung YH; Oh J; Hyeon DY; Kim Y; Lee S; Devkota S; Kim HJ; Park B; Nam T; Song Y; Kim Y; Hwang D; Lee HW
    Oncogene; 2020 Sep; 39(36):5876-5887. PubMed ID: 32728173
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tumor progression and chromatin landscape of lung cancer are regulated by the lineage factor GATA6.
    Arnal-Estapé A; Cai WL; Albert AE; Zhao M; Stevens LE; López-Giráldez F; Patel KD; Tyagi S; Schmitt EM; Westbrook TF; Nguyen DX
    Oncogene; 2020 Apr; 39(18):3726-3737. PubMed ID: 32157212
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Remodeling of the tumor/tumor microenvironment ecosystem during KRAS G12C inhibitor clinical resistance in lung cancer.
    Manabe T; Bivona TG
    J Clin Invest; 2022 Feb; 132(4):. PubMed ID: 35166243
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The superior efficacy of anti-PD-1/PD-L1 immunotherapy in KRAS-mutant non-small cell lung cancer that correlates with an inflammatory phenotype and increased immunogenicity.
    Liu C; Zheng S; Jin R; Wang X; Wang F; Zang R; Xu H; Lu Z; Huang J; Lei Y; Mao S; Wang Y; Feng X; Sun N; Wang Y; He J
    Cancer Lett; 2020 Feb; 470():95-105. PubMed ID: 31644929
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Osteopontin drives KRAS-mutant lung adenocarcinoma.
    Giopanou I; Kanellakis NI; Giannou AD; Lilis I; Marazioti A; Spella M; Papaleonidopoulos V; Simoes DCM; Zazara DE; Agalioti T; Moschos C; Magkouta S; Kalomenidis I; Panoutsakopoulou V; Lamort AS; Stathopoulos GT; Psallidas I
    Carcinogenesis; 2020 Aug; 41(8):1134-1144. PubMed ID: 31740923
    [TBL] [Abstract][Full Text] [Related]  

  • 38. ETS1 regulates Twist1 transcription in a Kras
    Millien G; Cao Y; O'Hara CJ; Tagne JB; Hinds A; Williams MC; Ramirez MI; Kathuria H
    Clin Exp Metastasis; 2018 Mar; 35(3):149-165. PubMed ID: 29909489
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The KRAS-G12C inhibitor: activity and resistance.
    Liu J; Kang R; Tang D
    Cancer Gene Ther; 2022 Jul; 29(7):875-878. PubMed ID: 34471232
    [TBL] [Abstract][Full Text] [Related]  

  • 40. KRAS as a Modulator of the Inflammatory Tumor Microenvironment: Therapeutic Implications.
    Pereira F; Ferreira A; Reis CA; Sousa MJ; Oliveira MJ; Preto A
    Cells; 2022 Jan; 11(3):. PubMed ID: 35159208
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.